Heikki Joensuu1, Mikael Eriksson2, Kirsten Sundby Hall3, Annette Reichardt4, Barbara Hermes5, Jochen Schütte6, Silke Cameron7, Peter Hohenberger8, Philipp J Jost9, Salah-Eddin Al-Batran10, Lars H Lindner11, Sebastian Bauer12, Eva Wardelmann13, Bengt Nilsson14, Raija Kallio15, Panu Jaakkola1, Jouni Junnila16, Thor Alvegård17, Peter Reichardt4. 1. Department of Oncology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland. 2. Department of Oncology, Skåne University Hospital and Lund University, Lund, Sweden. 3. Department of Oncology, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway. 4. Helios Klinikum Berlin-Buch, Sarkomzentrum Berlin-Brandenburg, Berlin, Germany. 5. Universitätsklinikum Tübingen, Tübingen, Germany. 6. Schwerpunktpraxis Oncology/Hematology, Düsseldorf, Germany. 7. Department of Gastroenterology, University of Göttingen, Göttingen, Germany. 8. Division of Surgical Oncology & Thoracic Surgery, Mannheim University Medical Center, Mannheim, Germany. 9. Medical Department III, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany. 10. Klinik für Onkologie und Hämatologie am Krankenhaus Nordwest, Frankfurt, Germany. 11. Department of Medicine III, University Hospital, LMU Munich, Munich, Germany. 12. Sarcoma Center, West German Cancer Center, Essen, Germany. 13. Gerhard-Domagk-Institute of Pathology, University of Münster, Münster, Germany. 14. Department of Surgery, Sahlgrenska University Hospital, Gothenburg, Sweden. 15. Department of Oncology and Radiotherapy, Oulu University Hospital, Oulu, Finland. 16. 4Pharma Ltd, Turku, Finland. 17. Department of Cancer Epidemiology, Lund University, Lund, Sweden.
Abstract
Importance: Adjuvant imatinib is associated with improved recurrence-free survival (RFS) when administered after surgery to patients with operable gastrointestinal stromal tumor (GIST), but its influence on overall survival (OS) has remained uncertain. Objective: To evaluate the effect of adjuvant imatinib on OS of patients who have a high estimated risk for GIST recurrence after macroscopically complete surgery. Design, Setting, and Participants: In this open-label, randomized (1:1), multicenter phase 3 clinical trial conducted in Finland, Germany, Norway, and Sweden, 400 patients who had undergone macroscopically complete surgery for GIST with a high estimated risk for recurrence according to the modified National Institutes of Health Consensus Criteria were enrolled between February 2004 and September 2008. Data for this follow-up analysis were analyzed from September to November, 2019. Interventions: Imatinib 400 mg/d administered orally for either 12 months or 36 months after surgery. Main Outcomes And Measures: The primary end point was RFS; the secondary objectives included OS and treatment safety. Results: The intention-to-treat cohort consisted of 397 patients (12-month group, 199; 36-month group, 198; 201 men and 196 women; median [IQR] age, 62 (51-69) years and 60 (51-67) years, during a median follow-up time of 119 months after the date of randomization, 194 RFS events and 96 OS events were recorded in the intention-to-treat population. Five-year and 10-year RFS was 71.4% and 52.5%, respectively, in the 36-month group and 53.0% and 41.8% in the 12-month group (hazard ratio [HR], 0.66; 95% CI, 0.49-0.87; P = .003). In the 36-month group, 5-year OS and 10-year OS rates were 92.0% and 79.0%, respectively, and in the 12-month group 85.5% and 65.3% (HR, 0.55; 95% CI, 0.37-0.83; P = .004). The results were similar in the efficacy population, from which 15 patients who did not have GIST in central pathology review and 24 patients who had intra-abdominal metastases removed at surgery were excluded (36-month group, 10-year OS 81.6%; 12-month group, 66.8%; HR, 0.50; 95% CI, 0.32-0.80; P = .003). No new safety signals were detected. Conclusions and Relevance: Three years of adjuvant imatinib is superior in efficacy compared with 1 year of imatinib. Approximately 50% of deaths may be avoided during the first 10 years of follow-up after surgery with longer adjuvant imatinib treatment. Trial Registration: ClinicalTrials.gov Identifier: NCT00116935.
RCT Entities:
Importance: Adjuvant imatinib is associated with improved recurrence-free survival (RFS) when administered after surgery to patients with operable gastrointestinal stromal tumor (GIST), but its influence on overall survival (OS) has remained uncertain. Objective: To evaluate the effect of adjuvant imatinib on OS of patients who have a high estimated risk for GIST recurrence after macroscopically complete surgery. Design, Setting, and Participants: In this open-label, randomized (1:1), multicenter phase 3 clinical trial conducted in Finland, Germany, Norway, and Sweden, 400 patients who had undergone macroscopically complete surgery for GIST with a high estimated risk for recurrence according to the modified National Institutes of Health Consensus Criteria were enrolled between February 2004 and September 2008. Data for this follow-up analysis were analyzed from September to November, 2019. Interventions: Imatinib 400 mg/d administered orally for either 12 months or 36 months after surgery. Main Outcomes And Measures: The primary end point was RFS; the secondary objectives included OS and treatment safety. Results: The intention-to-treat cohort consisted of 397 patients (12-month group, 199; 36-month group, 198; 201 men and 196 women; median [IQR] age, 62 (51-69) years and 60 (51-67) years, during a median follow-up time of 119 months after the date of randomization, 194 RFS events and 96 OS events were recorded in the intention-to-treat population. Five-year and 10-year RFS was 71.4% and 52.5%, respectively, in the 36-month group and 53.0% and 41.8% in the 12-month group (hazard ratio [HR], 0.66; 95% CI, 0.49-0.87; P = .003). In the 36-month group, 5-year OS and 10-year OS rates were 92.0% and 79.0%, respectively, and in the 12-month group 85.5% and 65.3% (HR, 0.55; 95% CI, 0.37-0.83; P = .004). The results were similar in the efficacy population, from which 15 patients who did not have GIST in central pathology review and 24 patients who had intra-abdominal metastases removed at surgery were excluded (36-month group, 10-year OS 81.6%; 12-month group, 66.8%; HR, 0.50; 95% CI, 0.32-0.80; P = .003). No new safety signals were detected. Conclusions and Relevance: Three years of adjuvant imatinib is superior in efficacy compared with 1 year of imatinib. Approximately 50% of deaths may be avoided during the first 10 years of follow-up after surgery with longer adjuvant imatinib treatment. Trial Registration: ClinicalTrials.gov Identifier: NCT00116935.
Authors: Maria Debiec-Rychter; Raf Sciot; Axel Le Cesne; Marcus Schlemmer; Peter Hohenberger; Allan T van Oosterom; Jean-Yves Blay; Serge Leyvraz; Michel Stul; Paolo G Casali; John Zalcberg; Jaap Verweij; Martine Van Glabbeke; Anne Hagemeijer; Ian Judson Journal: Eur J Cancer Date: 2006-04-18 Impact factor: 9.162
Authors: P G Casali; N Abecassis; H T Aro; S Bauer; R Biagini; S Bielack; S Bonvalot; I Boukovinas; J V M G Bovee; T Brodowicz; J M Broto; A Buonadonna; E De Álava; A P Dei Tos; X G Del Muro; P Dileo; M Eriksson; A Fedenko; V Ferraresi; A Ferrari; S Ferrari; A M Frezza; S Gasperoni; H Gelderblom; T Gil; G Grignani; A Gronchi; R L Haas; B Hassan; P Hohenberger; R Issels; H Joensuu; R L Jones; I Judson; P Jutte; S Kaal; B Kasper; K Kopeckova; D A Krákorová; A Le Cesne; I Lugowska; O Merimsky; M Montemurro; M A Pantaleo; R Piana; P Picci; S Piperno-Neumann; A L Pousa; P Reichardt; M H Robinson; P Rutkowski; A A Safwat; P Schöffski; S Sleijfer; S Stacchiotti; K Sundby Hall; M Unk; F Van Coevorden; W T A van der Graaf; J Whelan; E Wardelmann; O Zaikova; J Y Blay Journal: Ann Oncol Date: 2018-10-01 Impact factor: 32.976
Authors: Christopher L Corless; Karla V Ballman; Cristina R Antonescu; Violetta Kolesnikova; Robert G Maki; Peter W T Pisters; Martin E Blackstein; Charles D Blanke; George D Demetri; Michael C Heinrich; Margaret von Mehren; Shreyaskumar Patel; Martin D McCarter; Kouros Owzar; Ronald P DeMatteo Journal: J Clin Oncol Date: 2014-03-17 Impact factor: 44.544
Authors: Heikki Joensuu; Aki Vehtari; Jaakko Riihimäki; Toshirou Nishida; Sonja E Steigen; Peter Brabec; Lukas Plank; Bengt Nilsson; Claudia Cirilli; Chiara Braconi; Andrea Bordoni; Magnus K Magnusson; Zdenek Linke; Jozef Sufliarsky; Massimo Federico; Jon G Jonasson; Angelo Paolo Dei Tos; Piotr Rutkowski Journal: Lancet Oncol Date: 2011-12-06 Impact factor: 41.316
Authors: Heikki Joensuu; Mikael Eriksson; Kirsten Sundby Hall; Jörg T Hartmann; Daniel Pink; Jochen Schütte; Giuliano Ramadori; Peter Hohenberger; Justus Duyster; Salah-Eddin Al-Batran; Marcus Schlemmer; Sebastian Bauer; Eva Wardelmann; Maarit Sarlomo-Rikala; Bengt Nilsson; Harri Sihto; Odd R Monge; Petri Bono; Raija Kallio; Aki Vehtari; Mika Leinonen; Thor Alvegård; Peter Reichardt Journal: JAMA Date: 2012-03-28 Impact factor: 56.272
Authors: Paolo G Casali; Axel Le Cesne; Andres Poveda Velasco; Dusan Kotasek; Piotr Rutkowski; Peter Hohenberger; Elena Fumagalli; Ian R Judson; Antoine Italiano; Hans Gelderblom; Antoine Adenis; Jörg T Hartmann; Florence Duffaud; David Goldstein; Javier M Broto; Alessandro Gronchi; Angelo P Dei Tos; Sandrine Marréaud; Winette T A van der Graaf; John R Zalcberg; Saskia Litière; Jean-Yves Blay Journal: J Clin Oncol Date: 2015-11-16 Impact factor: 44.544
Authors: Charles D Blanke; George D Demetri; Margaret von Mehren; Michael C Heinrich; Burton Eisenberg; Jonathan A Fletcher; Christopher L Corless; Christopher D M Fletcher; Peter J Roberts; Daniela Heinz; Elisabeth Wehre; Zariana Nikolova; Heikki Joensuu Journal: J Clin Oncol Date: 2008-02-01 Impact factor: 44.544
Authors: Heikki Joensuu; Mikael Eriksson; Kirsten Sundby Hall; Annette Reichardt; Jörg T Hartmann; Daniel Pink; Giuliano Ramadori; Peter Hohenberger; Salah-Eddin Al-Batran; Marcus Schlemmer; Sebastian Bauer; Eva Wardelmann; Bengt Nilsson; Harri Sihto; Petri Bono; Raija Kallio; Jouni Junnila; Thor Alvegård; Peter Reichardt Journal: J Clin Oncol Date: 2015-11-02 Impact factor: 44.544
Authors: Joel W Neal; Daniel B Costa; Alona Muzikansky; Joseph B Shrager; Michael Lanuti; James Huang; Kavitha J Ramachandran; Deepa Rangachari; Mark S Huberman; Zofia Piotrowska; Mark G Kris; Christopher G Azzoli; Lecia V Sequist; Jamie E Chaft Journal: JCO Precis Oncol Date: 2021-02-01